Angela Genge

7.5k total citations
96 papers, 1.6k citations indexed

About

Angela Genge is a scholar working on Neurology, Genetics and Cellular and Molecular Neuroscience. According to data from OpenAlex, Angela Genge has authored 96 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Neurology, 37 papers in Genetics and 12 papers in Cellular and Molecular Neuroscience. Recurrent topics in Angela Genge's work include Amyotrophic Lateral Sclerosis Research (64 papers), Neurogenetic and Muscular Disorders Research (37 papers) and Parkinson's Disease Mechanisms and Treatments (24 papers). Angela Genge is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (64 papers), Neurogenetic and Muscular Disorders Research (37 papers) and Parkinson's Disease Mechanisms and Treatments (24 papers). Angela Genge collaborates with scholars based in Canada, United States and United Kingdom. Angela Genge's co-authors include Douglas L. Arnold, Sanjay Kalra, George Karpati, Neil R. Cashman, Nicola De Stefano, Paul M. Matthews, Lawrence Korngut, Lorne Zinman, Tanja Taivassalo and Zohar Argov and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Brain.

In The Last Decade

Angela Genge

89 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Angela Genge Canada 25 921 495 477 331 231 96 1.6k
Nazem Atassi United States 29 1.4k 1.6× 526 1.1× 804 1.7× 282 0.9× 397 1.7× 68 2.2k
Lora Clawson United States 24 1.8k 1.9× 592 1.2× 901 1.9× 689 2.1× 309 1.3× 36 2.6k
Pierre‐François Pradat France 30 2.6k 2.9× 669 1.4× 1.5k 3.2× 425 1.3× 364 1.6× 77 3.4k
Justin Kwan United States 14 614 0.7× 272 0.5× 204 0.4× 211 0.6× 260 1.1× 32 1.3k
Yusaku Nakamura Japan 18 445 0.5× 389 0.8× 74 0.2× 191 0.6× 231 1.0× 50 1.1k
Gholam Ali Shahidi Iran 22 947 1.0× 414 0.8× 63 0.1× 315 1.0× 282 1.2× 92 1.6k
Johanna Palmio Finland 27 465 0.5× 851 1.7× 208 0.4× 638 1.9× 168 0.7× 76 2.0k
Andrzej Friedman Poland 24 1.6k 1.8× 378 0.8× 58 0.1× 537 1.6× 586 2.5× 85 2.5k
Jeffrey Statland United States 32 796 0.9× 1.6k 3.2× 625 1.3× 1.0k 3.1× 216 0.9× 128 2.7k

Countries citing papers authored by Angela Genge

Since Specialization
Citations

This map shows the geographic impact of Angela Genge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angela Genge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angela Genge more than expected).

Fields of papers citing papers by Angela Genge

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angela Genge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angela Genge. The network helps show where Angela Genge may publish in the future.

Co-authorship network of co-authors of Angela Genge

This figure shows the co-authorship network connecting the top 25 collaborators of Angela Genge. A scholar is included among the top collaborators of Angela Genge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angela Genge. Angela Genge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Siddiqi, Zaeem A., et al.. (2025). Cost-Effectiveness Analysis of Efgartigimod vs Chronic Immunoglobulin for the Treatment of Myasthenia Gravis in Canada. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 1–12.
2.
Hewamadduma, Channa, Miriam Freimer, Angela Genge, et al.. (2025). Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis. Journal of Neurology. 272(7). 457–457. 2 indexed citations
3.
Siddiqi, Zaeem A., et al.. (2024). D.2 Cost-effectiveness analysis of efgartigimod vs chronic IVIg for treatment of patients with generalized myasthenia gravis in Canada. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 51(s1). S9–S9.
4.
Perrin, Steven, Shafeeq Ladha, Nicholas J. Maragakis, et al.. (2024). Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial. PLoS Medicine. 21(10). e1004469–e1004469. 2 indexed citations
5.
Benatar, Michael, Hannah Briemberg, Annie Dionne, et al.. (2024). Mismatch between clinically defined classification of ALS stage and the burden of cerebral pathology. Journal of Neurology. 271(5). 2547–2559. 1 indexed citations
6.
7.
Genge, Angela, Leonard H. van den Berg, Glen Frick, et al.. (2023). Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis. JAMA Neurology. 80(10). 1089–1089. 11 indexed citations
8.
Gwathmey, Kelly, Philippe Corcia, Christopher McDermott, et al.. (2023). Diagnostic delay in amyotrophic lateral sclerosis. European Journal of Neurology. 30(9). 2595–2601. 26 indexed citations
9.
Ross, Jay P., Fulya Akçimen, Calwing Liao, et al.. (2023). Rare-variant and polygenic analyses of amyotrophic lateral sclerosis in the French-Canadian genome. Genetics in Medicine. 26(1). 100967–100967. 1 indexed citations
10.
Picher‐Martel, Vincent, Pierre Cordeau, Hannah Kaneb, et al.. (2023). Distinct Plasma Immune Profile in ALS Implicates sTNFR-II in pAMPK/Leptin Homeostasis. International Journal of Molecular Sciences. 24(6). 5065–5065. 3 indexed citations
11.
Meng, Lisa, Stacy A. Rudnicki, Andrew A. Wolff, et al.. (2023). Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS. Journal of Medical Economics. 26(1). 488–493. 2 indexed citations
12.
Kushol, Rafsanjany, Collin Luk, Michael Benatar, et al.. (2023). SF2Former: Amyotrophic lateral sclerosis identification from multi-center MRI data using spatial and frequency fusion transformer. Computerized Medical Imaging and Graphics. 108. 102279–102279. 11 indexed citations
13.
Meng, Lisa, Stacy A. Rudnicki, Andrew A. Wolff, et al.. (2022). MiToS and King’s staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 24(3-4). 304–310. 3 indexed citations
14.
Luk, Collin, Abdullah Ishaque, Peter Seres, et al.. (2022). Motor cortex functional connectivity is associated with underlying neurochemistry in ALS. Journal of Neurology Neurosurgery & Psychiatry. 94(3). 193–200. 10 indexed citations
15.
Genge, Angela, Gary L. Pattee, Gen Sobue, et al.. (2022). 24-Week Results From Phase 3 Study MT-1186-A01 an Open-Label, Multicenter Safety Study of Oral Edaravone in Subjects With Amyotrophic Lateral Sclerosis (P1-13.001). Neurology. 98(18_supplement). 1 indexed citations
16.
Oskarsson, Björn, Nicholas J. Maragakis, Richard Bedlack, et al.. (2021). MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis in a Phase IIb/III Study: COMBAT-ALS Study Design. Neurodegenerative Disease Management. 11(6). 431–443. 29 indexed citations
17.
Wencel, Marie, Aziz Shaibani, Namita Goyal, et al.. (2021). Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices. Neurology Genetics. 7(6). e623–e623. 5 indexed citations
18.
Salmon, Kristiana, Matthew C. Kiernan, Seung Hyun Kim, et al.. (2021). The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis. Brain. 145(4). 1207–1210. 24 indexed citations
19.
Hodgkinson, Victoria, Bernard Brais, Kristine Chapman, et al.. (2021). A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Consensus using a Modified Delphi Method. Journal of Neuromuscular Diseases. 8(4). 579–588. 14 indexed citations
20.
Dadar, Mahsa, Ana L. Manera, Lorne Zinman, et al.. (2020). Cerebral atrophy in amyotrophic lateral sclerosis parallels the pathological distribution of TDP43. Brain Communications. 2(2). fcaa061–fcaa061. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nazem Atassi Breakdown of academic impact, for papers by Lora Clawson Breakdown of academic impact, for papers by Pierre‐François Pradat Breakdown of academic impact, for papers by Justin Kwan Breakdown of academic impact, for papers by Yusaku Nakamura Breakdown of academic impact, for papers by Gholam Ali Shahidi Breakdown of academic impact, for papers by Johanna Palmio Breakdown of academic impact, for papers by Andrzej Friedman Breakdown of academic impact, for papers by Jeffrey Statland
Rankless by CCL
2026